UBX Unity Biotechnology Inc.

6.83
-0.1  -1%
Previous Close 6.93
Open 6.96
Price To Book 2.73
Market Cap 313,782,153
Shares 45,941,750
Volume 161,519
Short Ratio
Av. Daily Volume 300,737
Stock charts supplied by TradingView

NewsSee all news

  1. UNITY Biotechnology, Inc. Reports Third Quarter 2019 Financial Results and Business Updates

    SAN FRANCISCO, Nov. 06, 2019 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) (NASDAQ:UBX), a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging,

  2. UNITY Biotechnology, Inc. Announces First Patient Dosed in Phase 2 Study of UBX0101 in Osteoarthritis of the Knee

    SAN FRANCISCO, Oct. 31, 2019 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) (NASDAQ:UBX), a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced that the

  3. UNITY Biotechnology, Inc. to Participate in the 2019 Cantor Global Healthcare Conference

    SAN FRANCISCO, Sept. 20, 2019 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY") (NASDAQ:UBX), a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of

  4. UNITY Biotechnology, Inc. to Participate in Upcoming Investor Conferences

    SAN FRANCISCO, Aug. 27, 2019 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY") (NASDAQ:UBX), a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 initiation of patient dosing announced November 11, 2019 with initial data due 2H 2020.
UBX0101
Osteoarthritis

Latest News

  1. UNITY Biotechnology, Inc. Reports Third Quarter 2019 Financial Results and Business Updates

    SAN FRANCISCO, Nov. 06, 2019 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) (NASDAQ:UBX), a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging,

  2. UNITY Biotechnology, Inc. Announces First Patient Dosed in Phase 2 Study of UBX0101 in Osteoarthritis of the Knee

    SAN FRANCISCO, Oct. 31, 2019 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) (NASDAQ:UBX), a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced that the

  3. UNITY Biotechnology, Inc. to Participate in the 2019 Cantor Global Healthcare Conference

    SAN FRANCISCO, Sept. 20, 2019 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY") (NASDAQ:UBX), a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of

  4. UNITY Biotechnology, Inc. to Participate in Upcoming Investor Conferences

    SAN FRANCISCO, Aug. 27, 2019 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY") (NASDAQ:UBX), a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of